Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Jae Myoung Noh; Jin Man Kim; Yong Chan Ahn; Hongryull Pyo; BoKyong Kim; Dongryul Oh; Sang Gyu Ju; Jin Sung Kim; Jung Suk Shin; Chae-Seon Hong; Hyojung Park; Eonju Lee

doi:10.4143/crt.2014.131

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(1); 2016 > Article

Original Article Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy: Jae Myoung Noh, MD, Jin Man Kim, BA, Yong Chan Ahn, MD, PhD, Hongryull Pyo, MD, PhD, BoKyong Kim, MD, PhD, Dongryul Oh, MD, Sang Gyu Ju, PhD, Jin Sung Kim, PhD, Jung Suk Shin, MS, Chae-Seon Hong, PhD, Hyojung Park, MD, Eonju Lee, MD; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(1):106-114.
DOI: https://doi.org/10.4143/crt.2014.131
Published online: February 12, 2015

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: Yong Chan Ahn, MD, PhD Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: 82-2-3410-2602 Fax: 82-2-3410-2619 E-mail: ahnyc@skku.edu

• Received: May 28, 2014 • Accepted: August 1, 2014

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

19,178 Views
155 Download
20 Web of Science
16 Crossref
20 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
This study was conducted to evaluate clinical outcomes following definitive concurrent chemoradiotherapy (CCRT) for patients with N3-positive stage IIIB (N3-IIIB) non-small cell lung cancer (NSCLC), with a focus on radiation therapy (RT) techniques.
Materials and Methods
From May 2010 to November 2012, 77 patients with N3-IIIB NSCLC received definitive CCRT (median, 66 Gy). RT techniques were selected individually based on estimated lung toxicity, with 3-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) delivered to 48 (62.3%) and 29 (37.7%) patients, respectively. Weekly docetaxel/paclitaxel plus cisplatin (67, 87.0%) was the most common concurrent chemotherapy regimen.
Results
The median age and clinical target volume (CTV) were 60 years and 288.0 cm³, respectively. Patients receiving IMRT had greater disease extent in terms of supraclavicular lymph node (SCN) involvement and CTV ≥ 300 cm³. The median follow-up time was 21.7 months. Fortyfive patients (58.4%) experienced disease progression, most frequently distant metastasis (39, 50.6%). In-field locoregional control, progression-free survival (PFS), and overall survival (OS) rates at 2 years were 87.9%, 38.7%, and 75.2%, respectively. Although locoregional control was similar between RT techniques, patients receiving IMRT had worse PFS and OS, and SCN metastases from the lower lobe primary tumor and CTV ≥ 300 cm³were associated with worse OS. The incidence and severity of toxicities did not differ significantly between RT techniques.
Conclusion
IMRT could lead to similar locoregional control and toxicity, while encompassing a greater disease extent than 3D-CRT. The decision to apply IMRT should be made carefully after considering oncologic outcomes associated with greater disease extent and cost.
Key words: Non-small cell lung carcinoma, Concurrent chemoradiotherapy, Stage IIIB-N3, Intensity-modulated radiotherapy

Introduction

Definitive concurrent chemoradiotherapy (CCRT) has become the standard treatment for patients with N3-positive stage IIIB (N3-IIIB) non-small cell lung cancer (NSCLC) [1-4]. Delivery of high radiation dose, which is usually recommended for improved locoregional control and survival [5], is often limited by the risk of lung toxicity, which presents as radiation pneumonitis and subsequent pulmonary fibrosis [6,7]. The extent of metastatic regional lymph nodes (LN) in patients with N3-IIIB NSCLC is quite heterogeneous [8], and it often becomes difficult to safely cover the whole disease extent within the high radiation dose volume when using conventional 3-dimensional conformal radiation therapy (3D-CRT) technique. Metastasis to the supraclavicular lymph node (SCN) from the lower lobe primary tumor is a typical problematic example. Introduction of the intensity-modulated radiation therapy (IMRT) technique has greatly improved the target coverage at high radiation dose while sparing normal lung tissue [9-11]. Previous studies that employed IMRT were more or less successful at achieving favorable clinical outcomes in terms of locoregional control and survival and reducing the incidences of pulmonary and esophageal toxicities, among which the proportion of patients with N3 or IIIB disease accounted for 32%-60% [12-14]. Based on these studies, the use of IMRT for treatment of patients with stage III NSCLC has become increasingly popular [15].

The use of IMRT is still limited in Korea, mainly because the national health insurance plan covers only the 3D-CRT technique and does not reimburse the cost of IMRT during treatment of patients with NSCLC. Given this limitation, few clinical studies on the use of IMRT for lung cancer patients have been conducted in Korea [16]. Since May of 2010, the authors at Samsung Medical Center (SMC) have been using IMRT to treat patients with extensive NSCLC. Based on their known disease extent, these patients were believed to be at excessive risk of pulmonary toxicity if treated with conventional 3D-CRT. This study was conducted to comparatively evaluate treatment outcomes based on the radiation therapy (RT) techniques chosen (IMRT vs. 3D-CRT) for evaluation of N3-IIIB NSCLC patients receiving definitive CCRT.

Materials and Methods

From May 2010 to November 2012, 81 patients with newly diagnosed, pathologically confirmed N3-IIIB NSCLC were treated with definitive CCRT at SMC. Since trimodality therapy strategy, which includes surgical resection following neoadjuvant CCRT, has been the primary treatment option for N2-IIIA patients at SMC [17], patients with N3-IIIB disease constituted the majority of those receiving definitive CCRT. Among these, two patients received curative surgical resection following definitive CCRT, and another two received a combination of 3D-CRT and IMRT. After excluding these four patients, we retrospectively reviewed the medical records of 77 patients who were the basis of the current study. The RT techniques were selected individually based on the known disease extent, performance and cardiopulmonary functional status of the patients, and the subsequent estimated risk of pulmonary toxicity. When the estimated V₂₀ exceeded 40%, the mean lung dose exceeded 25 Gy, and/or the maximum spinal cord dose exceeded 50 Gy if treated with conventional 3D-CRT, they were offered the IMRT option. It was explained to all the IMRT candidate patients that IMRT was not covered by the Korean insurance policy, and they were offered alternative option of induction chemotherapy followed by sequential RT in case the IMRT cost was not affordable. All IMRT candidate patients agreed to pay the extra-cost, and the current study was approved by the Institutional Review Board of Samsung Medical Center (2013-08-027).

The initial diagnosis of NSCLC was pathologically confirmed in all patients based on either bronchoscopy or percutaneous fine-needle aspiration and biopsy. The diagnostic and staging work-ups included complete history and physical examination, simple chest radiographs, chest computed tomography (CT) scan, routine blood tests, and ¹⁸fluoro-deoxyglucose positron emission tomography (PET) or PET/CT scan. For accurate nodal staging, fine-needle aspiration from the SCN was performed in 33 patients (42.9%), endobronchial ultrasound-guided transbronchial needle aspiration in 29 (37.7%), and mediastinoscopic biopsy in nine (9.1%). N3 stage assignment was made primarily based on clinical judgment without histologic confirmation in 15 patients (19.5%) who showed abnormal findings on PET/CT scan and were at very high risk to undergo any invasive procedures.

For treatment planning, contrast enhancing simulation CT scans of all patients were conducted. Simulation CT scans were typically performed in the supine position at a thickness of 2.5-5 mm. The gross tumor volume (GTV) was defined as the volume of the tumor identified based on all available clinical information, including radiologic imaging, PET scan, bronchoscopy, and mediastinoscopy. The clinical target volume (CTV) was delineated by a 5-mm margin extending in all directions from the GTV, and the margins were modified in accordance with the adjacent organs if necessary. The internal target volume was delineated by combining all GTVs and CTVs delineated on each respiratory phase based on 4-dimensional computed tomography (4D-CT), which was acquired in 29 patients (37.7%). Elective irradiation of the clinically uninvolved lymph node was not allowed principally. A 5-8 mm margin extension around the CTV was included to generate the planning target volume. The Pinnacle³ system (ver. 8.0, Philips Medical Systems, Madison, WI) was used to calculate the radiation dose.

During the study period, 48 patients (62.3%) were treated with 3D-CRT (group I) and 29 (37.7%) with IMRT (group II). The median RT dose prescribed to the CTV was 66 Gy in 33 fractions over 6.5 weeks. The 3D-CRT plan was typically composed of three or four beams of 4-, 6-, or 10-MV photons from a linear accelerator (Varian Medical System, Palo Alto, CA). The IMRT plan was mainly composed of six median coplanar beams of 6-MV photons using the step-and-shoot method. Whenever feasible and indicated, the second CT simulation and adaptive re-plan was generated to accommodate tumor regression and reduce the normal tissue toxicity, typically at fractions of 20-23. The normal tissue constraints used were as follows: maximum spinal cord dose < 46 Gy; relative lung volumes receiving 20 Gy/5 Gy < 35%/< 65%; and the mean lung dose < 20 Gy. The most common concurrent chemotherapeutic regimen was weekly paclitaxel or docetaxel plus cisplatin or carboplatin, which was administered to 67 patients (87.0%). Ten of these patients received additional consolidation chemotherapy following CCRT. The remaining ten patients (13.0%) received pemetrexed or etoposide plus cisplatin, while nine of these patients received consolidation chemotherapy.

The first follow-up and response evaluation was scheduled at 1 month after completion of CCRT and included a chest CT scan. Subsequent follow-up evaluations were conducted at 3-4 month intervals thereafter, and included alternating chest CT and whole-body PET/CT scans. The early toxicities of treatment-related pneumonitis (TRP) and esophagitis were graded using the Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0. The primary endpoints were the progression-free survival (PFS) and the overall survival (OS), while the secondary endpoints were the in-field locoregional control (LRC) and patterns of disease progression. All intervals were calculated from the dates of the CCRT start until the events or the latest follow-up. In-field locoregional progression was defined as disease progression within the irradiated volume inside the thorax, and included the ipsilateral hilum, ipsilateral and/or contralateral mediastinum, and ipsilateral and/or contralateral SCN, but not hematogenous lung-to-lung metastasis.

A chi-square test was used to compare the patients’ clinical characteristics and the dose-volume parameters based on the RT techniques used. A t test was used to compare continuous variables such as age, forced expiratory volume in 1 second, and tumor size. The rates of PFS, OS, and LRC were calculated and compared using the Kaplan-Meier method and the log-rank test, respectively. Factors having a p-value of < 0.2 upon univariate analysis were entered into Cox proportional hazards regression analysis. A p-value of ≤ 0.05 was considered statistically significant, and the SAS software (ver. 9.1.3, SAS Institute Inc., Cary, NC) was used for statistical analyses.

Results

The clinical characteristics based on the RT techniques are summarized in Table 1. The median age of all patients was 60 years (range, 40 to 80 years). Age, sex, smoking history, performance status, and clinical T classification did not differ between groups. Adenocarcinoma was the most common histology (53 patients, 68.8%), followed by squamous cell carcinoma (18 patients, 23.4%). The median tumor size measured on the initial CT was 3.8 cm (range, 1.0 to 12.2 cm). Group II (IMRT) patients had significantly more frequent primary tumors located in the lower lobes (p=0.001) and SCN involvement (p=0.011) than group I (3D-CRT). Among 50 patients with SCN involvement, 16 had primary tumors located in the lower lobes, which was also more frequent in group II than in group I (13/24 patients, 54.2% vs. 3/26 patients, 11.5%). The median CTV of all patients was 288.0 cm³ (range, 89.3 to 1,543.3 cm³). Although the median CTV tended to be larger in group II than group I (3D-CRT), this difference was not statistically significant according to a t test (p=0.706) (Table 2). When the CTVs were stratified into groups (< 300 cm³ vs. ≥ 300 cm³), group II was associated with larger CTV more frequently than group I (p=0.043). Since patients receiving IMRT generally had a greater extent of disease, the mean lung and heart doses were higher in group II than in group I. However, the normal tissue doses generally met the constraints described above. Among the 16 patients with SCN metastasis from the lower lobe primary tumors, dose-volume parameters for the lungs and esophagus were generally similar (Fig. 1).

The median follow-up duration was 21.7 months (range, 2.3 to 43.1 months). During the follow-up period, 45 patients (58.4%) experienced disease progression (Table 3). The most common first failure pattern was distant metastasis observed in 39 patients (50.6%), followed by locoregional progression in 13 patients (16.9%). Among 13 patients with locoregional failure, nine showed progression within the RT volume, six from group I and three from group II. There were seven patients (9.1%) who presented with both locoregional and distant progression. The organs involved via distant metastasis were the lung in 12 patients, the brain in nine, bone in eight, and the liver in five. The median duration of PFS was 11.1 months, and the 1- and 2-year rates of PFS were 47.9% and 38.7%, respectively (Fig. 2). The 1- and 2-year rates of in-field LRC were 87.9% and 85.0%, respectively. A total of 18 patients (23.4%) died during the follow-up period. Pulmonary causes, such as pneumonia, pneumonitis, and acute respiratory distress syndrome, were responsible for the deaths of two patients, one from group I and the other from group II, while TRP was not the direct cause of death for two patients. In addition, one patient died of myocardial infarction. The 1- and 2-year rates of OS were 85.5% and 75.2%, respectively (Fig. 2). The incidence of CTACE grade 3 esophagitis was 19.5%, which was not different between groups I and II (14.6% vs. 27.6%, p=0.163). Although patients receiving IMRT had significantly larger disease extent and received higher lung dose, the incidence of grade ≥ 2 pneumonitis was not higher in group II than group I (33.3% vs. 24.1%, p=0.393). Among the 16 patients with SCN metastasis from the lower lobe primary tumor, grade ≥ 2 pneumonitis developed in three patients, one from group I and two from group II. Grade 3 esophagitis occurred in four patients in group II.

The clinical outcomes based on the probable prognostic factors are summarized in Tables 4 and 5. According to univariate analyses, IMRT technique (p=0.001), age < 60 years (p=0.019), and non-squamous cell carcinoma histology (p=0.002) were associated with significantly poor PFS, while IMRT technique (p=0.007), SCN metastasis from the lower lobe primary tumor (p=0.019), and CTV ≥ 300 cm³ (p=0.001) were associated with significantly poor OS. Gender, clinical T stage, and SCN involvement itself were not of prognostic value to the clinical outcomes. No specific factor was known to have affected the in-field LRC. Based on multivariate analyses, IMRT technique (p=0.010) and age < 60 years (p=0.032) were significant poor prognostic factors affecting the PFS. Interestingly, the RT technique was not a significant factor affecting the OS (p=0.197), while a CTV ≥ 300 cm³ was the only factor that had a significant effect on the OS (p=0.018).

Discussion

Few studies have reported the treatment outcomes following IMRT for NSCLC [12-14,16,18]. These previous studies not only included patients with stage IIIB disease, but also those with stage IIIA and even stages I/II. Although the current study included only N3-IIIB patients, the disease extent was still quite heterogeneous because of differences in the location of metastatic LNs and the CTVs. Despite definitive CCRT being the standard treatment option for patients with N3-IIIB NSCLC, 3D-CRT cannot safely deliver high radiation doses cases of large disease extent, especially in those involving SCN metastasis from lower lobe primary tumors, because of the normal tissue toxicity risk. Based on previously conducted studies, IMRT could result in significantly lower levels of grade ≥ 3 TRP when compared with 3D-CRT, despite the large GTVs [12]. Furthermore, a subsequent study showed that IMRT with 4D-CT was associated with reduced toxicity and improved OS [13]. Following the median follow-up of 16.5 months, the 2-year rates of disease-free survival and OS were 38% and 46%, respectively [14].

Patients receiving IMRT in the current study had significantly more frequent SCN metastasis from the lower lobe primary tumor and significantly larger CTVs than those receiving 3D-CRT. Even though group II patients had a larger disease extent and were therefore subjected to higher normal tissue doses, the incidences of grade 3 esophagitis and grade ≥ 2 pneumonitis were not increased in this group based on the current study. Moreover, a comparable in-field LRC was achieved, while more frequent distant metastases occurred in patients receiving IMRT. While the 2-year rates of PFS and OS following definitive CCRT for patients with N3-IIIB NSCLC were 38.7% and 75.2%, respectively, the corresponding rates of patients receiving IMRT were 19.3% and 61.7%, respectively (Table 4). However, direct comparison of the clinical outcomes between groups I and II should be made with caution because of the evident heterogeneity of the clinical characteristics. Although patients receiving IMRT had unfavorable survival outcomes, this might have occurred because these patients already had more adverse prognostic factors than those receiving 3D-CRT. The PFS at 2 years reported in this study seems inferior to that of previous studies (19.3% vs. 38%). This difference might have been due to the heterogeneous patient population with respect to stage, tumor location, and extent of nodal involvement. One retrospective study of IMRT reported a 2-year OS rate of 58% in stage III patients [18], and the corresponding figure by the authors appears to be generally favorable when compared with the previous data. Taken together, IMRT could safely cover a larger disease extent than 3D-CRT, and yielded a favorable in-field LRC with no extra toxicity risk.

As shown in Table 3, the median time to progression following IMRT was only 6 months, and this was mostly due to early appearance of distant metastases. Interestingly, the OS was not as poor as the PFS in the current study. It is important to note that clinical outcomes following disease progression might be influenced by the availability of systemic treatment regimens, including targeting agents, which were not presented in detail in the current study. Although collection of biomarker data such as mutations in the epidermal growth factor receptor (EGFR) gene and/or anaplastic lymphoma kinase (ALK) gene was not the primary objective of the current study, 13 (24.5%) and five (9.4%) of 53 patients with adenocarcinoma exhibited EGFR gene mutations and ALK rearrangements, respectively. Furthermore, 16 of these 18 patients exhibited disease progression, mostly distant metastases. In patients with N2-positive NSCLC, EGFR mutation was shown to experience more frequent distant relapse and have worse PFS following preoperative CCRT and surgery at SMC [19]. CCRT accompanied by treatment with cetuximab, a monoclonal antibody targeting EGFR, has demonstrated promising outcomes in patients with stage III NSCLC [20,21]. Moreover, favorable clinical outcomes have been reported in patients treated with the ALK tyrosine-kinase inhibitor, crizotinib [22]. Therefore, further improvement of clinical outcomes in the patients receiving definitive CCRT for N3-IIIB NSCLC could be expected if combining these targeting agents with RT.

As described above, the Surveillance, Epidemiology, and End Results (SEER) data demonstrated increased use of IMRT for patients with stage III NSCLC [15]. A radiation oncologists’ practice environment can strongly influence utilization of the IMRT technique. Similarly, the reimbursement policies and practice settings were shown to have a great effect on utilization of IMRT for treatment of patients with breast cancer [23]. IMRT appears to have been utilized less frequently than necessary in Korea, mainly because the national health insurance system does not reimburse patients for this technique. The high cost of IMRT for lung cancer could be a considerable financial burden, resulting in financial toxicity [24,25]. Therefore, careful and reasonable decision making with consideration of the cost effectiveness should become a crucially important issue for the optimal utilization of up-to-date technologies and resources. Future research efforts should be directed toward solving these issues and development of biological markers.

Conclusion

The current study has several limitations, including a small number of patients, great heterogeneity in disease extent, and potential selection bias owing to the economic capacity of the patients. Nevertheless, the authors were able to demonstrate that IMRT was capable of delivering high radiation dose with no extra risk of lung toxicity in a definitive CCRT setting for treatment of N3-IIIB NSCLC patients, especially those with extensive disease, such as lower lobe primary tumor with SCN metastasis. Since the early occurrence of distant metastasis was a major pattern of disease progression, careful patient selection and optimal combinations of systemic treatments, including targeting agents, are necessary to improve clinical outcomes.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Dose-volume parameters for lung and esophagus in patients with supraclavicular lymph node (SCN) originating from a lower lobe primary tumor. 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; LV5 and LV20, volumes of the normal lung received ≥ 5 Gy and ≥ 20 Gy; MLD, mean lung dose; EV30 and EV45, volumes of the normal esophagus received ≥ 30 Gy and ≥ 45 Gy; MED, mean esophagus dose. Data are presented as the mean±standard error.

Fig. 2.

Progression-free survival (PFS) and overall survival (OS) after definitive concurrent chemoradiotherapy in patients with N3-positive stage IIIB non-small cell lung cancer.

Table 1.

Clinical characteristics according to radiotherapy technique

Characteristic	3D-CRT (n=48)	IMRT (n=29)	p-value
Age (yr)	62 (44-72)	59 (40-80)	0.744
Sex
Male	35 (72.9)	18 (62.1)	0.390
Female	13 (27.1)	11 (37.9)
Smoking history	34 (70.8)	17 (58.6)	0.272
FEV₁ (L)	2.49 (1.17-3.90)	2.50 (1.46-3.71)	0.791
ECOG performance
0	10 (20.8)	6 (20.7)	0.988
1	38 (79.2)	23 (79.3)
Primary site
Upper-middle lobes	39 (81.3)	13 (44.8)	0.001
Lower lobes	9 (18.7)	16 (55.2)
Histology
Adenocarcinoma	31 (64.6)	22 (75.9)	0.053
Squamous cell carcinoma	15 (31.2)	3 (10.3)
Others	2 (4.2)	4 (13.8)
Tumor size (cm)	3.8 (1.3-12.2)	3.7 (1.0-9.2)	0.785
Clinical T classification
cT1-2	34 (70.8)	23 (79.3)	0.411
cT3-4	14 (29.2)	6 (20.7)
N3 involvement region
Contralateral mediastinum	29 (60.4)	7 (24.1)	0.002
Supraclavicular	26 (54.2)	24 (82.8)	0.011

Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; FEV₁, forced expiratory volume in 1 second; ECOG, Eastern Cooperative Oncology Group.

Table 2.

Dose-volume parameters according to radiotherapy techniques

Variable	3D-CRT (n=48)	IMRT (n=29)	p-value
CTV (cm³)	279.3 (89.4-1,543.3)	357.5 (89.3-762.7)	0.706
CTV
< 300 cm³	28 (59.3)	10 (34.5)	0.043
≥ 300 cm³	20 (41.7)	19 (65.5)
Total lung
Mean dose (Gy)	18.4 (9.3-28.0)	19.6 (14.6-25.2)	0.031
V₅(%)	57.2 (29.8-72.9)	65.1 (48.4-90.0)	< 0.001
V₁₀ (%)	48.6 (24.5-63.5)	51.8 (41.8-62.9)	0.107
V₁₅ (%)	40.6 (18.1-54.5)	42.3 (34.7-53.6)	0.052
V₂₀ (%)	32.8 (14.3-50.0)	35.6 (28.2-45.9)	0.061
Esophagus
Maximum dose (Gy)	67.1 (55.3-74.7)	68.4 (60.0-77.3)	0.007
Mean dose (Gy)	33.2 (12.5-55.8)	35.1 (16.1-52.0)	0.111
V₃₀ (%)	52.1 (15.2-87.7)	55.9 (15.8-79.6)	0.520
V₄₅ (%)	44.2 (3.7-74.9)	48.8 (1.2-76.5)	0.526
Spinal cord
Maximum dose (Gy)	43.9 (10.5-57.4)	43.1 (32.3-48.4)	0.708
Heart
Median dose (Gy)	8.6 (0.5-42.4)	16.4 (1.5-35.0)	0.001

Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; CTV, clinical target volume; V_D, percentage volume of organ receiving ≥ D Gy.

Table 3.

Outcomes according to treatment groups

Variable	3D-CRT (n=48)	IMRT (n=29)	Overall (n=77)
Disease progression	24 (50.0)	21 (72.4)	45 (58.4)
Time to progression (mo)	9.1 (3.9-35.0)	6.0 (2.5-15.9)	8.2 (2.5-35.0)
Patterns of failures
Locoregional	4 (8.3)	2 (6.9)	6 (7.8)
Distant	17 (35.4)	15 (51.7)	32 (41.6)
Both	3 (6.3)	4 (13.8)	7 (9.1)
Esophagitis
Grade ≤ 2	41 (85.4)	21 (72.4)	62 (80.5)
Grade 3	7 (14.6)	8 (27.6)	15 (19.5)
Pneumonitis
Grade 1	32 (66.7)	22 (75.9)	54 (70.1)
Grade ≥ 2	16 (33.3)	7 (24.1)	23 (29.9)

Values are presented as number (%) or median (range). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy.

Table 4.

Prognostic factors affecting survival outcomes upon univariate analysis in patients with N3-positive stage IIIB non-small cell lung cancer

Variable	No.	PFS		OS		In-field LRC
Variable	No.	2-Year rate (%)	p-value	2-Year rate (%)	p-value	2-Year rate (%)	p-value
Treatment group
3D-CRT	48	50.10	0.001	83.50	0.007	89.40	0.432
IMRT	29	19.30		61.70		72.40
Sex
Male	53	42.50	0.229	71.00	0.311	83.40	0.740
Female	24	30.10		85.20		87.50
Age (yr)
< 60	35	22.90	0.019	77.00	0.753	92.30	0.635
≥ 60	42	54.00		74.50		80.60
Histology
Adenocarcinoma	53	28.70	0.002	75.60	0.160	83.70	0.636
Squamous cell carcinoma	18	75.00		83.30		86.70
Others	6	16.70		44.40		83.30
Clinical T classification
cT1-2	48	38.70	0.904	76.80	0.722	85.10	0.948
cT3-4	29	39.00		70.00		85.20
SCN involvement
Yes	50	34.20	0.320	75.30	0.894	83.50	0.686
No	27	46.30		74.50		86.60
SCN from lower lobe
Yes	16	23.50	0.160	60.60	0.019	80.00	0.856
No	61	42.20		79.10		85.70
Clinical target volume (cm³)
< 300	38	46.00	0.139	91.20	0.001	88.40	0.834
≥ 300	39	31.00		59.10		80.10

PFS, progression-free survival; OS, overall survival; LRC, locoregional control; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; SCN, supraclavicular lymph node.

Table 5.

Cox proportional hazards multivariate model for survival outcomes

Variable	Progression-free survival		Overall survival
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Treatment group	2.498 (1.246-5.008)	0.010	2.160 (0.670-6.965)	0.197
Age	0.514 (0.280-0.943)	0.032	-	-
Histology	0.876 (0.490-1.564)	0.654	1.253 (0.657-2.390)	0.494
SCN from lower lobe	0.872 (0.379-2.003)	0.747	1.554 (0.490-4.927)	0.454
CTV (≥ 300 cm³)	1.549 (0.834-2.879)	0.166	4.665 (1.298-16.766)	0.018

HR, hazard ratio; CI, confidence interval; SCN, supraclavicular lymph node; CTV, clinical target volume.

REFERENCES

1. National Comprehensive Cancer Network. NCCN guidelines version 3, 2014. Non-small cell lung cancer [Internet] . Fort Washington, PA: National Comprehensive Cancer Network; 2014. [cited 2014 May 28] . Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
2. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90. Article PubMed
3. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60. Article PubMed PMC
4. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e314S–40S. Article PubMed
5. Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82:425–34. Article PubMed PMC
6. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys. 2007;67:410–6. Article PubMed
7. Oh D, Ahn YC, Park HC, Lim DH, Han Y. Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors. Jpn J Clin Oncol. 2009;39:151–7. Article PubMed
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2009.
9. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57:875–90. Article PubMed
10. Liu HH, Wang X, Dong L, Wu Q, Liao Z, Stevens CW, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1268–79. Article PubMed
11. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1258–67. Article PubMed
12. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of treatment-related pneumonitis in advancedstage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:94–102. Article PubMed
13. Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:775–81. Article PubMed
14. Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012;83:332–9. Article PubMed
15. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer. 2013;82:252.Article PubMed PMC
16. Song CH, Pyo H, Moon SH, Kim TH, Kim DW, Cho KH. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2010;78:651.Article PubMed
17. Lee H, Ahn YC, Pyo H, Kim B, Oh D, Nam H, et al. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. Ann Surg Oncol. 2014;21:2083–90. Article PubMed
18. Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol. 2008;87:17–23. Article PubMed PMC
19. Ahn HK, Choi YL, Han JH, Ahn YC, Kim K, Kim J, et al. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer. 2013;79:300–6. Article PubMed
20. Ready N, Janne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010;5:1382–90. Article PubMed
21. Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011;29:2312–8. Article PubMed PMC
22. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004–12. Article PubMed PMC
23. Smith BD, Pan IW, Shih YC, Smith GL, Harris JR, Punglia R, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011;103:798–809. Article PubMed
24. Chino F, Peppercorn J, Taylor DH Jr, Lu Y, Samsa G, Abernethy AP, et al. Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist. 2014;19:414.Article PubMed PMC
25. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–90. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chong Han, Jingping Qiu, Lu Bai, Tingting Liu, Jun Chen, He Wang, Jun Dang
International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1179. CrossRef
“Mid-P strategy” versus “internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P
Line Claude, Camille Schiffler, Vanina Isnardi, Séverine Metzger, Sophie Darnis, Isabelle Martel-Lafay, Thomas Baudier, Simon Rit, David Sarrut, Myriam Ayadi
Radiotherapy and Oncology.2024; 199: 110435. CrossRef
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Tingting Liu, Sihan Li, Silu Ding, Jingping Qiu, Chengbo Ren, Jun Chen, He Wang, Xiaoling Wang, Guang Li, Zheng He, Jun Dang
eClinicalMedicine.2023; 64: 102246. CrossRef
The effect of radiotherapy and surgery on stage IIIA/B NSCLC patients treated with chemotherapy
Y. Zeng, G. Wang, H. Zheng, Y. Wang, G. Ma, Z. Pang, J. Du
International Journal of Radiation Research.2023; 21(3): 475. CrossRef
Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
Life.2022; 12(2): 292. CrossRef
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Impact of Supraclavicular Lymph Node Involvement of Stage IIIC Non-Small Cell Lung Cancer Patients
Sunmin Park, Won Sup Yoon, Mi Hee Jang, Chai Hong Rim
Medicina.2021; 57(3): 301. CrossRef
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
Radiation Oncology Journal.2021; 39(1): 24. CrossRef
Comparaison dosimétrique et de la toxicité de la radiothérapie conformationnelle avec modulation d’intensité et de la radiothérapie conformationnelle tridimensionnelle des carcinomes bronchiques non à petites cellules
F. Guillemin, L. Berger, M. Lapeyre, A. Bellière-Calandry
Cancer/Radiothérapie.2021; 25(8): 747. CrossRef
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
Lung Cancer.2020; 146: 23. CrossRef
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
Rocco Giannicola, Graziella D'Arrigo, Cirino Botta, Rita Agostino, Pietro Del Medico, Antonia Falzea, Vito Barbieri, Nicoletta Staropoli, Teresa Del Giudice, Pierpaolo Pastina, Valerio Nardone, Marika Monoriti, Graziella Calabrese, Giovanni
Molecular and Clinical Oncology.2019;[Epub] CrossRef
Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
Min Wei, Qingqing Ye, Xuan Wang, Men Wang, Yan Hu, Yonghua Yang, Jiyuan Yang, Jun Cai
Medicine.2018; 97(19): e0632. CrossRef
Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer
John Boyle, Brad Ackerson, Lin Gu, Chris R. Kelsey
Advances in Radiation Oncology.2017; 2(1): 6. CrossRef
Normal lung sparing Tomotherapy technique in stage III lung cancer
Chae-Seon Hong, Sang Gyu Ju, Yong Chan Ahn, Gyu Sang Yoo, Jae Myoung Noh, Dongryul Oh, Kwangzoo Chung, Hongryull Pyo, Kwanghyun Jo
Radiation Oncology.2017;[Epub] CrossRef
Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry
Pierre Truntzer, Delphine Antoni, Nicola Santelmo, Catherine Schumacher, Pierre-Emmanuel Falcoz, Elisabeth Quoix, Gilbert Massard, Georges Noël
Reports of Practical Oncology & Radiotherapy.2016; 21(5): 427. CrossRef
Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer
Minal S. Kale, Grace Mhango, Marcelo Bonomi, Alex Federman, Keith Sigel, Kenneth E. Rosenzweig, Juan P. Wisnivesky
Annals of the American Thoracic Society.2016; 13(9): 1593. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Cancer Res Treat. 2016;48(1):106-114. Published online February 12, 2015

DOI: https://doi.org/10.4143/crt.2014.131

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Analysis of Once-Daily Thoracic Radiotherapy Dose According to the Underlying Lung Disease in Patients with Limited-Stage Small Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy

Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Fig. 1. Dose-volume parameters for lung and esophagus in patients with supraclavicular lymph node (SCN) originating from a lower lobe primary tumor. 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; LV5 and LV20, volumes of the normal lung received ≥ 5 Gy and ≥ 20 Gy; MLD, mean lung dose; EV30 and EV45, volumes of the normal esophagus received ≥ 30 Gy and ≥ 45 Gy; MED, mean esophagus dose. Data are presented as the mean±standard error.

Fig. 2. Progression-free survival (PFS) and overall survival (OS) after definitive concurrent chemoradiotherapy in patients with N3-positive stage IIIB non-small cell lung cancer.

Fig. 1.

Fig. 2.

Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Characteristic	3D-CRT (n=48)	IMRT (n=29)	p-value
Age (yr)	62 (44-72)	59 (40-80)	0.744
Sex
Male	35 (72.9)	18 (62.1)	0.390
Female	13 (27.1)	11 (37.9)
Smoking history	34 (70.8)	17 (58.6)	0.272
FEV₁ (L)	2.49 (1.17-3.90)	2.50 (1.46-3.71)	0.791
ECOG performance
0	10 (20.8)	6 (20.7)	0.988
1	38 (79.2)	23 (79.3)
Primary site
Upper-middle lobes	39 (81.3)	13 (44.8)	0.001
Lower lobes	9 (18.7)	16 (55.2)
Histology
Adenocarcinoma	31 (64.6)	22 (75.9)	0.053
Squamous cell carcinoma	15 (31.2)	3 (10.3)
Others	2 (4.2)	4 (13.8)
Tumor size (cm)	3.8 (1.3-12.2)	3.7 (1.0-9.2)	0.785
Clinical T classification
cT1-2	34 (70.8)	23 (79.3)	0.411
cT3-4	14 (29.2)	6 (20.7)
N3 involvement region
Contralateral mediastinum	29 (60.4)	7 (24.1)	0.002
Supraclavicular	26 (54.2)	24 (82.8)	0.011

Variable	3D-CRT (n=48)	IMRT (n=29)	p-value
CTV (cm³)	279.3 (89.4-1,543.3)	357.5 (89.3-762.7)	0.706
CTV
< 300 cm³	28 (59.3)	10 (34.5)	0.043
≥ 300 cm³	20 (41.7)	19 (65.5)
Total lung
Mean dose (Gy)	18.4 (9.3-28.0)	19.6 (14.6-25.2)	0.031
V₅(%)	57.2 (29.8-72.9)	65.1 (48.4-90.0)	< 0.001
V₁₀ (%)	48.6 (24.5-63.5)	51.8 (41.8-62.9)	0.107
V₁₅ (%)	40.6 (18.1-54.5)	42.3 (34.7-53.6)	0.052
V₂₀ (%)	32.8 (14.3-50.0)	35.6 (28.2-45.9)	0.061
Esophagus
Maximum dose (Gy)	67.1 (55.3-74.7)	68.4 (60.0-77.3)	0.007
Mean dose (Gy)	33.2 (12.5-55.8)	35.1 (16.1-52.0)	0.111
V₃₀ (%)	52.1 (15.2-87.7)	55.9 (15.8-79.6)	0.520
V₄₅ (%)	44.2 (3.7-74.9)	48.8 (1.2-76.5)	0.526
Spinal cord
Maximum dose (Gy)	43.9 (10.5-57.4)	43.1 (32.3-48.4)	0.708
Heart
Median dose (Gy)	8.6 (0.5-42.4)	16.4 (1.5-35.0)	0.001

Variable	3D-CRT (n=48)	IMRT (n=29)	Overall (n=77)
Disease progression	24 (50.0)	21 (72.4)	45 (58.4)
Time to progression (mo)	9.1 (3.9-35.0)	6.0 (2.5-15.9)	8.2 (2.5-35.0)
Patterns of failures
Locoregional	4 (8.3)	2 (6.9)	6 (7.8)
Distant	17 (35.4)	15 (51.7)	32 (41.6)
Both	3 (6.3)	4 (13.8)	7 (9.1)
Esophagitis
Grade ≤ 2	41 (85.4)	21 (72.4)	62 (80.5)
Grade 3	7 (14.6)	8 (27.6)	15 (19.5)
Pneumonitis
Grade 1	32 (66.7)	22 (75.9)	54 (70.1)
Grade ≥ 2	16 (33.3)	7 (24.1)	23 (29.9)

Variable	No.	PFS		OS		In-field LRC
Variable	No.	2-Year rate (%)	p-value	2-Year rate (%)	p-value	2-Year rate (%)	p-value
Treatment group
3D-CRT	48	50.10	0.001	83.50	0.007	89.40	0.432
IMRT	29	19.30		61.70		72.40
Sex
Male	53	42.50	0.229	71.00	0.311	83.40	0.740
Female	24	30.10		85.20		87.50
Age (yr)
< 60	35	22.90	0.019	77.00	0.753	92.30	0.635
≥ 60	42	54.00		74.50		80.60
Histology
Adenocarcinoma	53	28.70	0.002	75.60	0.160	83.70	0.636
Squamous cell carcinoma	18	75.00		83.30		86.70
Others	6	16.70		44.40		83.30
Clinical T classification
cT1-2	48	38.70	0.904	76.80	0.722	85.10	0.948
cT3-4	29	39.00		70.00		85.20
SCN involvement
Yes	50	34.20	0.320	75.30	0.894	83.50	0.686
No	27	46.30		74.50		86.60
SCN from lower lobe
Yes	16	23.50	0.160	60.60	0.019	80.00	0.856
No	61	42.20		79.10		85.70
Clinical target volume (cm³)
< 300	38	46.00	0.139	91.20	0.001	88.40	0.834
≥ 300	39	31.00		59.10		80.10

Variable	Progression-free survival		Overall survival
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Treatment group	2.498 (1.246-5.008)	0.010	2.160 (0.670-6.965)	0.197
Age	0.514 (0.280-0.943)	0.032	-	-
Histology	0.876 (0.490-1.564)	0.654	1.253 (0.657-2.390)	0.494
SCN from lower lobe	0.872 (0.379-2.003)	0.747	1.554 (0.490-4.927)	0.454
CTV (≥ 300 cm³)	1.549 (0.834-2.879)	0.166	4.665 (1.298-16.766)	0.018

Table 1. Clinical characteristics according to radiotherapy technique

Table 2. Dose-volume parameters according to radiotherapy techniques

Table 3. Outcomes according to treatment groups

Values are presented as number (%) or median (range). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy.

Table 4. Prognostic factors affecting survival outcomes upon univariate analysis in patients with N3-positive stage IIIB non-small cell lung cancer

Table 5. Cox proportional hazards multivariate model for survival outcomes

HR, hazard ratio; CI, confidence interval; SCN, supraclavicular lymph node; CTV, clinical target volume.